Antiretroviral drugs work by blocking HIV at specific stages of its life cycle, preventing the virus from making copies of itself inside your body. HIV goes through seven distinct stages to reproduce, and modern drugs can interrupt nearly every one of them. By combining drugs that target different stages, treatment can reduce the amount of virus in your blood to undetectable levels, typically within six months.
How HIV Reproduces Inside Your Cells
To understand what antiretroviral drugs are doing, it helps to know what they’re up against. HIV targets a specific type of immune cell called a CD4 cell, one of the key players in your body’s defense system. The virus hijacks these cells to make more copies of itself, destroying them in the process. Left untreated, this gradually dismantles your immune system.
The virus reproduces in seven stages: it binds to the surface of a CD4 cell, fuses with the cell’s outer membrane and slips inside, converts its own genetic material from RNA into DNA, inserts that DNA into the cell’s own genetic code, uses the cell’s machinery to produce new viral proteins, assembles those proteins into immature virus particles, and finally pushes new copies out of the cell to infect others. Each of these stages depends on specific enzymes or interactions that drugs can disrupt.
Blocking the Virus From Entering Cells
The first opportunity to stop HIV is before it even gets inside a CD4 cell. To enter, the virus first latches onto a receptor on the cell’s surface using a protein on its outer shell called gp120. After that initial grab, gp120 changes shape and reaches for a second receptor, usually one called CCR5. Only after connecting to both receptors can the virus fuse its outer membrane with the cell and release its contents inside.
Entry inhibitors work by blocking that first attachment. CCR5 antagonists physically sit on the CCR5 receptor, preventing the virus from making its second connection. This is effective against viral strains that rely on CCR5 to enter cells, which are the most common type. Fusion inhibitors take a different approach, preventing the viral envelope from merging with the cell membrane even after the virus has attached. Either way, the result is the same: HIV stays locked outside the cell.
Stopping the Virus From Copying Its Genes
Once HIV enters a CD4 cell, it needs to convert its RNA (its genetic blueprint) into DNA. The virus carries its own enzyme for this job, called reverse transcriptase. Two entire classes of antiretroviral drugs target this single step, because it’s one of the most vulnerable points in the whole cycle.
The first class, NRTIs (nucleoside reverse transcriptase inhibitors), are essentially decoys. They mimic the building blocks that reverse transcriptase uses to construct new DNA. When the enzyme grabs one of these fake building blocks and snaps it into the growing DNA chain, construction stops. The decoy is missing a chemical component needed to attach the next piece, so the chain can’t continue. It’s like slipping a dead-end piece into a puzzle.
The second class, NNRTIs (non-nucleoside reverse transcriptase inhibitors), takes a completely different approach. Instead of posing as building blocks, these drugs bind directly to the reverse transcriptase enzyme near its active site, warping its shape. With its structure distorted, the enzyme works far less efficiently and DNA synthesis slows dramatically. One important limitation: NNRTIs only work against HIV-1, the most common type worldwide, because the reverse transcriptase enzyme in HIV-2 has a different shape that these drugs can’t latch onto.
Preventing the Virus From Hijacking Your DNA
If the virus successfully converts its RNA into DNA, the next step is slipping that viral DNA into the cell’s own genetic code. HIV uses an enzyme called integrase to cut open the cell’s DNA and stitch in the viral version. Once integrated, the viral instructions become a permanent part of that cell’s genome, and the cell will produce new virus particles every time it’s activated.
Integrase inhibitors (called INSTIs) block this enzyme, preventing viral DNA from merging with the cell’s DNA. This is a critical intervention point: without integration, the virus can’t establish a lasting foothold. INSTIs are now the backbone of most first-line treatment regimens because they’re highly effective, well tolerated, and tend to drive viral levels down quickly.
Disrupting Assembly and Maturation
Even after HIV has commandeered a cell to produce new viral proteins, drugs can still intervene. As the cell churns out long chains of viral protein, those chains need to be cut into smaller, functional pieces before the new virus particles become infectious. HIV relies on its own enzyme, protease, to make these cuts.
Protease inhibitors mimic the proteins that protease normally cuts, binding to the enzyme’s active site and preventing it from doing its job. The result is dramatic: even partial interference with protease activity leads to severe defects in the new virus particles. Research has shown that even when viral proteins appear to be nearly fully processed, the resulting particles still fail to become infectious. They end up with malformed internal structures that simply don’t work. Some newer protease inhibitors can also prevent the protease enzyme from assembling in the first place, adding a second layer of disruption.
Capsid inhibitors are a newer class that interfere with the protein shell surrounding the virus’s genetic material. By disrupting this shell during assembly, they prevent functional virus particles from forming.
Why Combination Therapy Is Essential
HIV mutates rapidly. Every time the virus copies itself, small errors creep into its genetic code. Most of these mutations are harmless or even harmful to the virus, but occasionally one makes the virus less susceptible to a particular drug. If only one drug is being used, those resistant variants can quickly multiply and take over.
Resistance mutations develop when the virus is exposed to drug concentrations high enough to create pressure but low enough to still allow some replication. This is why missed doses are a real concern. Inconsistent drug levels open that window where resistant strains have a survival advantage.
Combination therapy closes that window by attacking the virus at multiple stages simultaneously. A virus that develops resistance to one drug still gets blocked by the other two. The standard approach pairs two NRTIs with a drug from another class, most commonly an integrase inhibitor. Current U.S. guidelines recommend regimens built around second-generation integrase inhibitors like bictegravir or dolutegravir, combined with two NRTIs. For some patients, a simplified two-drug regimen of dolutegravir plus lamivudine is an option.
How Quickly Treatment Works
Once you start antiretroviral therapy, viral levels in your blood begin dropping within days. Doctors monitor your viral load at two to four weeks, then every four to eight weeks after that. Most people reach an undetectable viral load within six months, though many get there faster. “Undetectable” means the amount of virus is so low that standard tests can’t measure it. At that level, the virus can’t be transmitted sexually, a principle known as U=U (undetectable equals untransmittable).
Reaching undetectable doesn’t mean the virus is gone. HIV integrates its DNA into long-lived immune cells that can harbor the virus for years in a dormant state. If treatment stops, the virus re-emerges from these reservoirs. This is why antiretroviral therapy is a lifelong commitment.
Long-Acting Injectable Options
Daily pills aren’t the only option anymore. A long-acting injectable regimen combining cabotegravir (an integrase inhibitor) and rilpivirine (an NNRTI) can be given as two shots every one or two months, replacing daily oral medication entirely. In a large clinical trial called ATLAS-2M, injections given every two months maintained viral suppression as effectively as monthly injections over 96 weeks, with confirmed treatment failure occurring in only about 2% of participants on the every-two-month schedule.
Lenacapavir, a capsid inhibitor, takes this even further with dosing every six months. These options are particularly valuable for people who struggle with daily pill regimens or who want more privacy around their treatment.
The Role of Boosters
Some antiretroviral drugs are broken down by the body too quickly to maintain effective levels between doses. To solve this, certain regimens include a pharmacokinetic booster: a small dose of a drug whose only job is to slow down the liver enzyme (CYP3A4) that metabolizes the main medication. By inhibiting that enzyme, the booster keeps blood levels of the active drug higher for longer, allowing lower or less frequent dosing. Ritonavir and cobicistat are the two boosters currently used, and they appear in several fixed-dose combination pills.